MedPath

ong-term study of HOB-294 in patients with overactive bladder.

Phase 3
Conditions
Overactive bladder
Registration Number
JPRN-jRCT2080221273
Lead Sponsor
Hisamitsu Pharmaceutical Co., Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with symptoms of overactive bladder for at least 24 weeks before obtaining informed consent

Exclusion Criteria

- Patients with genuine stress incontinence
- Patients with micturition difficulty, retention of urine, or other symptoms due to lower urinary tract obstruction
- Patients for whom it is difficult to walk to the lavatory without assistance, patients who cannot measure the urine volume by themselves, and patients who cannot keep a bladder log by themselves

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety, Efficacy
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath